COVID-19 Pre-exposure Prevention with Evusheld

U.S. Food and Drug Administration issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals.

This pre-exposure treatment is not a substitute for a COVID-19 vaccine.

AstraZeneca’s Evusheld

The product is only authorized for those individuals who are not currently infected with the SARS-CoV-2 virus and who have not recently been exposed to an individual infected with SARS-CoV-2. The authorization also requires that individuals either have:

  • Moderate to severely compromised immune systems due to a medical condition or due to taking immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination (examples of such medical conditions or treatments can be found in the fact sheet for health care providers) or;
  • A history of severe adverse reactions to a COVID-19 vaccine and/or component(s) of those vaccines, therefore vaccination with an available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended.
  • Evusheld is not authorized for individuals for the treatment of COVID-19 or for post-exposure prevention of COVID-19. Patients should talk with their health care provider to determine whether Evusheld is an appropriate pre-exposure prevention option for them.
  • Pre-exposure prevention with Evusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. 

Schedule your Virtual Visit Today

If you would like to speak with one of our providers about Evusheld and whether or not you would be a good candidate for pre-exposure prevention, please schedule your Virtual Visit by clicking the button below.